Xeris Pharmaceuticals
XERS
16.97
+0.35
+2.11%
Xeris Pharmaceuticals
US · XERS
#2862 by market cap
Listed 2018
16.97
+0.35
+2.11%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:57
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 8 in the most recent period (2026/Q3).
- Total institutional ownership fell 1.0 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 64.16% -1.01pp
- Institutions
- 290 +8
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund41.11%
Hedge Fund14.44%
Public Company4.69%
Individual/Insider3.38%
Insurance Company1.32%
Private Company0.89%
Government Pension Fund0.88%
Sovereign Wealth Fund0.46%
VC/PE Fund0.26%
Other32.56%
Top holders as of 2026-09-30
BlackRock
8.02% · 14.66M sh
D. E. Shaw & Co., L.P.
4.27% · 7.80M sh
Vanguard Capital Management, LLC
4.22% · 7.71M sh
State Street Global Advisors
3.05% · 5.57M sh
Geode Capital Management, LLC
2.50% · 4.57M sh
Teachers Insurance and Annuity Association-College Retirement Equities Fund
2.33% · 4.25M sh
Rosalind Advisors, Inc.
1.59% · 2.91M sh
Qube Research & Technologies Ltd
1.58% · 2.89M sh
Vanguard Portfolio Management, LLC
1.45% · 2.65M sh
Morgan Stanley
1.41% · 2.58M sh
Nuveen Asset Management LLC
1.32% · 2.41M sh
Wellington Management Group
1.30% · 2.37M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 17 buys · 33 sells
| Name | Role | Stake |
|---|---|---|
| Kevin McCulloch | President | 0.87% |
| John Shannon | Chairperson & CEO | 0.85% |
| Steven Pieper | Chief Financial Officer | 0.50% |
| John Johnson | Independent Non-Executive Director | 0.37% |
| Beth Hecht | Chief Legal Officer | 0.32% |
| Garheng Albert Kong | Independent Non-Executive Director | 0.12% |
| Jeffrey Sherman | Former Independent Director | 0.10% |
| Marla Persky | Lead Independent Director | 0.07% |
| Barbar-Jean Bormann-Kennedy | Independent Director | 0.07% |
| Dawn Halkuff | Independent Director | 0.05% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-04 | Kevin McCulloch | President | Automatic Disposition | -25,000 | $12.49 |
| 2026-11-01 | Beth Hecht | Chief Legal Officer | Automatic Disposition | -25,000 | $10.23 |
| 2026-11-01 | Kevin McCulloch | President | Automatic Disposition | -15,000 | $10.23 |
| 2026-11-01 | Menassie Taddese | Director | Other Acquisition | +22,365 | -- |
| 2026-11-01 | Menassie Taddese | Director | Other Derivative Disposition | -31,499 | $10.17 |
| 2026-11-01 | Steven Pieper | Chief Financial Officer | Automatic Disposition | -5,000 | $10.23 |
| 2026-09-30 | Beth Hecht | Chief Legal Officer | Automatic Disposition | -16,666 | $9.41 |
| 2026-09-30 | Kevin McCulloch | President | Automatic Disposition | -15,000 | $9.41 |
| 2026-09-30 | Steven Pieper | Chief Financial Officer | Automatic Disposition | -5,000 | $9.41 |
| 2026-09-27 | Kevin McCulloch | President | Automatic Disposition | -25,000 | $10.00 |
| 2026-08-31 | Beth Hecht | Chief Legal Officer | Automatic Disposition | -16,666 | $8.49 |
| 2026-08-31 | Kevin McCulloch | President | Automatic Disposition | -15,000 | $8.49 |
| 2026-08-31 | Steven Pieper | Chief Financial Officer | Automatic Disposition | -5,000 | $8.50 |
| 2026-08-11 | Steven Pieper | Chief Financial Officer | Automatic Disposition | -5,000 | $8.50 |
| 2026-08-02 | Beth Hecht | Chief Legal Officer | Automatic Disposition | -16,666 | $8.01 |
| 2026-08-02 | Kevin McCulloch | President | Automatic Disposition | -15,000 | $8.02 |
| 2026-07-31 | John Shannon | Chairperson & CEO | Sale to Issuer | -36,645 | $8.08 |
| 2026-07-31 | Kevin McCulloch | President | Sale to Issuer | -21,918 | $8.08 |
| 2026-07-06 | Steven Pieper | Chief Financial Officer | Automatic Disposition | -45,000 | $8.50–8.52 |
| 2026-07-06 | Steven Pieper | Chief Financial Officer | Intent to Sell (Form 144) | -27,600 | $8.37 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:57:17 · For reference only, not investment advice and not tailored to your situation.
Xeris Pharmaceuticals discussion 0 comments